

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Health Technology Appraisal

**Omalizumab for the treatment of severe persistent allergic asthma
(review of TA133 and TA201)**

Final matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Novartis (omalizumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action Against Allergy • Action for Children • Action for Sick Children • Afiya Trust • Allergy UK • Anaphylaxis Campaign • Asthma UK • Black Health Agency • British Lung Foundation • Children's Society • Counsel and Care • Equalities National Council • Muslim Council of Britain • Muslim Health Network • National Children's Bureau • National Parent Partnership Network • South Asian Health Foundation • Specialised Healthcare Alliance • Wellchild <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Respiratory Nurse Specialists • British Association for Services to the Elderly • British Geriatrics Society • British Paediatric Respiratory Society • British Society for Allergy & Clinical Immunology • British Thoracic Society • Primary Care Respiratory Society • Royal College of General Practitioners 	<p><u>General</u></p> <ul style="list-style-type: none"> • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Commissioning Support Appraisals Service • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Public Health Wales NHS Trust • Scottish Medicines Consortium <p><u>Comparator manufacturer(s)</u></p> <ul style="list-style-type: none"> • None <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Asthma, Allergy and Inflammation Research Trust • Cochrane Airways Group • MRC and Asthma UK Centre in Allergic Mechanisms of Asthma • MRC Clinical Trials Unit • National Institute for Health Research • National Society for Research into Allergy • Research Institute for the Care of Older People

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal College of Nursing • Royal College of Paediatrics and Child Health • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • United Kingdom Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS Halton and St Helens • NHS Hounslow • Welsh Government 	<p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> • National Institute for Health Research Health Technology Assessment Programme • NHS Centre for Reviews & Dissemination and Centre for Health Economics <p><u>Associated Guideline groups</u> National Clinical Guideline Centre</p> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • tbc

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

Definitions:Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology are invited to prepare a submission dossier, can respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical specialists and/or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment group

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies)) based on a systematic review of the manufacturer/sponsor and non-manufacturer/sponsor submission dossier to the Institute.